Methotrexate Drug Market Size, Share, Trends & Forecast by 2034

Methotrexate Drug Market Outlook from 2024 to 2034

The methotrexate drug market is expected to develop at a CAGR of 5.5% during the projected period. The market value is projected to increase from US$ 621.3 million in 2024 to US$ 1,058 million by 2034.

Attributes	Details
Estimated Methotrexate Drug Market Size, 2024	US$ 621.3 million
Forecasted Methotrexate Drug Market Size, 2034	US$ 1,058 million
Projected Value CAGR (2024 to 2034)	5.5%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Methotrexate Drug Market Overview

The upsurge in the prevalence of chronic diseases, such as autoimmune and cancer worldwide. Doctors and other health professionals are actively prescribing methotrexate as an effective treatment. Thus, methotrexate is gaining popularity as a primary drug for such treatment. Moreover, the growing geriatric population is expected to drive the demand for methotrexate drugs. Aging people have a rapid rate of disease suffering.

The rise of biosimilars is anticipated to drive demand for the methotrexate drug industry. In the current period, there is a growing need for affordable alternative drugs that function the same way as branded drugs. Therefore, the methotrexate drug market benefits from biosimilars. Furthermore, these alternatives allow patients who have previously been unable to afford them to do so.

Advances in the drug delivery system are expected to contribute to the market growth. Some drug delivery methods, such as injectable formulations, offer more convenient and easier administration of methotrexate. This not only upturns the patient's convenience but also the drug demand.

The rising awareness and acceptance of alternative therapies also drive the methotrexate drug industry. As more patients seek complementary and different treatments for their health conditions, methotrexate emerges as an effective option worldwide. Consumer preference for alternative therapies leads to demand for the drug, particularly in integrative medicine.

Healthcare Spending and Improved Infrastructure Presents Lucrative Market Opportunities

The methotrexate injection market has huge growth potential, driven by a surge in healthcare spending and infrastructure improvements, especially in emerging nations. Injectable technologies and drug delivery systems can make methotrexate injections more patient-compliant, convenient, and safe.

Personalizing medical care for patients based on their unique characteristics is gaining ground, and methotrexate injections can be incorporated into individualized treatment plans. As precision medicine methods continue to advance, there are likely to be opportunities to optimize dosage methods and improve treatment outcomes.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Restraining Factors in the Methotrexate Drug Market

A stringent regulatory compliance process is expected to hamper the market expansion during the forecast period. Methotrexate drugs, such as high-risk drugs, have lengthy and complex regulatory approval processes. Complying with regulatory regulations and receiving regulatory bodies' approvals is expected to be a key challenge in the industry.

The challenges lead to cost fluctuations and delays. Several governments have implemented strict rules regarding Regulatory compliance, drug safety, and others.

The use of methotrexate injections includes several risks and negative side effects. Safety issues and reports of unfavorable events are expected to hinder the patient's acceptance of the drug. Some of the key concerns with methotrexate injections are their savior complications and life-threatening reactions that occur shortly after receiving the medication. Safety concerns and negative reports are anticipated to have a negative impact on the market.

The availability and cost of methotrexate injections is a major restraining factor for the current period. This availability and cost are expected to be impacted by pricing and reimbursement policies. The pricing and reimbursement policies are structured differently for the different countries. Policies are making it difficult for manufacturers to enter the market and gain potential.

Category-wise Insights

In terms of Material Type, the Rheumatoid Arthritis Segment Leads the Market Growth

Attributes	Details
Indication	Rheumatoid Arthritis
Forecasted Market CAGR from 2024 to 2034	5.3%

Methotrexate injections are used in the treatment of rheumatoid arthritis conditions which is considered the standard of care for rheumatoid arthritis complications which is primarily driving demand.
Methotrexate works by suppressing the immune system and eliminating inflammation, and it is gaining popularity among patients due to its benefits. For instance, the Centers for Disease Control and Prevention (CDC) published a report that about 1.5 million people in the United States have rheumatoid arthritis.
The incidence of autoimmune diseases like psoriasis and Crohn's disease is on the rise which is broadening the potential market for methotrexate drugs.
Surging healthcare expenditure in emerging economies is also expected to contribute to the growth of the segment.

In terms of Manufacturing Mode, the In-house Manufacturing Segment Dominates the Market

Attributes	Details
Application	In-house Manufacturing
Forecasted Market CAGR from 2024 to 2034	5.1%

Cost-effectiveness is anticipated to drive growth for the segment in the coming years.
Manufacturers can now reduce their costs through in-house manufacturing by eliminating the cost of outsourcing production to third-party manufacturers.
The need for quality control is also expected to drive the demand for the segment.
In-house manufacturing provides greater control over the manufacturing process from sourcing raw materials to checking product quality and safety.

Country-wise insights

Countries	Forecasted CAGR from 2024 to 2034
United States	5.7%
United Kingdom	5.7%
China	5.9%
Japan	7.0%
South Korea	6.9%

Interest in Integrative Medicines is Skyrocketing in the United States

Rising concerns regarding cancer and autoimmune diseases in the United States is fueling market growth. For instance, according to the American Cancer Society, 1.9 million new cancer cases were diagnosed in 2022, and 609,360 cancer deaths were detected in the surveillance.

Expanding healthcare expenditure is anticipated to drive demand for methotrexate drugs in the United States. For greater access to medical treatment and to handle expanded infrastructure, the United States is investing heavily in infrastructure. The rising shift toward value-based care is contributing to the market expansion.

Rising interest in integrative medicines in the United States is expected to create lucrative opportunities in the market. Combining traditional Western medicine with complementary therapies, integrative medicine is gaining traction in the United States market.

Rising Use of the Biosimilar in the United Kingdom

The aging population is driving demand for methotrexate drugs in the United Kingdom. In the United Kingdom, a rise in diseases like cancer, particularly among older individuals, has fueled the growth of the methotrexate drug market.

The use of biosimilar in the United Kingdom is on the rise. The cost-effectiveness among consumers in the United Kingdom is expected to drive the adoption of methotrexate drugs during the forecast period. Biosimilar methotrexate has been approved in the United Kingdom and is expected to drive down the cost of the drug, making it more accessible to patients.

The availability of the different formulations of methotrexate drugs is backing up the expansion of the industry in the United Kingdom. Methotrexate is available in tablets, injections, and oral solutions, giving patients and healthcare professionals more options for treatment in the United Kingdom.

Growing Middle-class Population in China Sparks Demand through Affordability

Research and development activities in the pharmaceutical industry in China are spurring market growth. As more technologies and treatments are developed, the use of methotrexate drugs is increasing in China.

The growing middle-class population in China is anticipated to drive the sale of methotrexate. As people's incomes rise, they can spend more money on advanced treatments and better healthcare facilities. Methotrexate is considered a relatively affordable option compared to other cancer treatments, making it more accessible to the middle-class population in China.

Growing Awareness among the Population about the Early Detection of diseases such as cancer and others in Japan

The government has been supporting the development and use of methotrexate in Japan by providing subsidies to hospitals and clinics that use the drug. This has helped to reduce the cost of the drug and make it more accessible to patients.

Growing awareness among the population about the importance of early detection and treatment of cancer and other chronic diseases in Japan is evident. This has led to a surge in demand for advanced treatments like methotrexate.

Methotrexate is considered to be a relatively safe and effective drug with a long history of use in the treatment of cancer and autoimmune diseases. It is also relatively inexpensive compared to other cancer treatments, which makes it an attractive option for patients and healthcare providers in Japan.

Methotrexate is also used to treat autoimmune diseases like rheumatoid arthritis, which has been on the rise in Japan. This is partly due to the aging population and changes in lifestyle and environmental factors.

South Korea’s Advanced Healthcare Systems Support Market Expansion

South Korea has one of the most advanced healthcare systems in the world, and the government has been increasing its spending on healthcare in recent years. The advanced healthcare system has made it easier for people to access advanced treatments like methotrexate, which has contributed to the demand for methotrexate drugs.

Biosimilar drugs are similar to existing biological drugs but produced by a different manufacturer. In recent years, the availability of biosimilars for methotrexate has been seen in South Korea. This has helped reduce the drug's cost and make it more accessible to patients.

Competitive Landscape

The market is highly competitive, with several companies operating in the space. Companies are competing on factors such as price, product quality, innovation, and distribution channels. Moreover, other smaller players or vendors in the market produce generic versions of methotrexate drugs.

The competition in the market is expected to intensify during the forecast period owing to the increasing demand for methotrexate and the entry of new players in the market. Companies in the market are also investing heavily in research and development to develop new and improved methotrexate products that can provide better outcomes for patients.

Recent Development

In 2023, Jylamvo, the first and only oral Methotrexate solution approved by the FDA for use by adults in the United States, was commercially launched in the country by Shorla Oncology and EVERSANA.
In 2022, a new treatment option for Rheumatoid Arthritis was introduced in Japan, and the Metoject® Subcutaneous Injection Syringe, which contains Methotrexate, was launched.
In 2020, Cumberland Pharmaceuticals Inc. launched a new product called RediTrex injection. This prefilled syringe is specifically designed for subcutaneous administration of methotrexate in patients with rheumatoid arthritis and psoriasis. The product is designed to make it easy for patients to use and to provide precise dosing. RediTrex is a convenient and user-friendly option for patients who need to self-administer methotrexate at home.

Key Market Players

Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
Sandoz International GmbH
Fresenius Kabi AG
Mylan N.V.
Sun Pharmaceutical Industries Ltd.
Aspen Pharmacare Holdings Limited
Amneal Pharmaceuticals LLC
Hikma Pharmaceuticals PLC.

Key Coverage in the Methotrexate Drug Market Report

Methotrexate Therapy Market Report
Methotrexate Cancer Treatment Market Analysis
Methotrexate Pharmaceutical Industry Assessment
Global Methotrexate Injection Market Overview
Methotrexate In Rheumatoid Arthritis Treatment Pricing Outlook

Key Market Segments

By Indication:

Psoriasis
Rheumatoid Arthritis
Cancer
Other Indications

By Manufacturing Mode:

In-house Manufacturing
Contract Manufacturing

By Synthesis Type:

Chemical Based API
Highly Potent API (HPAPI)

By Region:

North America
Latin America
East Asia
South Asia
Europe
Oceania
MEA

Frequently Asked Questions

What is China’s Methotrexate Drug Market Outlook?

The market in China is expected to progress at a CAGR of 5.9% through the forecast period.

How Big is the Methotrexate Drug Market in 2024?

The market is currently valued at around US$ 621.3 million in 2024.

Which Indication Segment Contributes More to the Methotrexate Drug Market?

Within the indication, the rheumatoid arthritis segment is expected to register a 5.3% market CAGR from 2024 to 2034.

What is the United States Methotrexate Drug Market Outlook?

The market in the United States is set to register 5.7% CAGR from 2024 to 2034.

What is the Projected Value for the Methotrexate Drug Market by 2034?

The market is set to reach a valuation of around US$ 1,058 million by 2034-end.

What Was the Historical CAGR for the Methotrexate Drug Market?

Demand for methotrexate drugs increased at 7.2% CAGR from 2019 to 2023.

Table of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Manufacturer
3.5.1.2. Mid-Level Participants (Traders)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Indication, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Indication, 2024 to 2034
5.3.1. Psoriasis
5.3.2. Rheumatoid Arthritis
5.3.3. Cancer
5.3.4. Other Indications
5.4. Y-o-Y Growth Trend Analysis By Indication, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Indication, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Manufacturing Mode
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Manufacturing Mode, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Manufacturing Mode, 2024 to 2034
6.3.1. In-House Manufacturing
6.3.2. Contract Manufacturing
6.4. Y-o-Y Growth Trend Analysis By Manufacturing Mode, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Manufacturing Mode, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Synthesis Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Synthesis Type, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Synthesis Type, 2024 to 2034
7.3.1. Chemical Based API
7.3.2. Highly Potent API (HPAPI)
7.4. Y-o-Y Growth Trend Analysis By Synthesis Type, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Synthesis Type, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023
8.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Indication
9.2.3. By Manufacturing Mode
9.2.4. By Synthesis Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Indication
9.3.3. By Manufacturing Mode
9.3.4. By Synthesis Type
9.4. Key Takeaways
10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Indication
10.2.3. By Manufacturing Mode
10.2.4. By Synthesis Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Indication
10.3.3. By Manufacturing Mode
10.3.4. By Synthesis Type
10.4. Key Takeaways
11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Indication
11.2.3. By Manufacturing Mode
11.2.4. By Synthesis Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Indication
11.3.3. By Manufacturing Mode
11.3.4. By Synthesis Type
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Indication
12.2.3. By Manufacturing Mode
12.2.4. By Synthesis Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Indication
12.3.3. By Manufacturing Mode
12.3.4. By Synthesis Type
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Indication
13.2.3. By Manufacturing Mode
13.2.4. By Synthesis Type
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Indication
13.3.3. By Manufacturing Mode
13.3.4. By Synthesis Type
13.4. Key Takeaways
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Indication
14.2.3. By Manufacturing Mode
14.2.4. By Synthesis Type
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Indication
14.3.3. By Manufacturing Mode
14.3.4. By Synthesis Type
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Indication
15.2.3. By Manufacturing Mode
15.2.4. By Synthesis Type
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Indication
15.3.3. By Manufacturing Mode
15.3.4. By Synthesis Type
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2023
16.1.2.1. By Indication
16.1.2.2. By Manufacturing Mode
16.1.2.3. By Synthesis Type
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2023
16.2.2.1. By Indication
16.2.2.2. By Manufacturing Mode
16.2.2.3. By Synthesis Type
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2023
16.3.2.1. By Indication
16.3.2.2. By Manufacturing Mode
16.3.2.3. By Synthesis Type
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2023
16.4.2.1. By Indication
16.4.2.2. By Manufacturing Mode
16.4.2.3. By Synthesis Type
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2023
16.5.2.1. By Indication
16.5.2.2. By Manufacturing Mode
16.5.2.3. By Synthesis Type
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2023
16.6.2.1. By Indication
16.6.2.2. By Manufacturing Mode
16.6.2.3. By Synthesis Type
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2023
16.7.2.1. By Indication
16.7.2.2. By Manufacturing Mode
16.7.2.3. By Synthesis Type
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2023
16.8.2.1. By Indication
16.8.2.2. By Manufacturing Mode
16.8.2.3. By Synthesis Type
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2023
16.9.2.1. By Indication
16.9.2.2. By Manufacturing Mode
16.9.2.3. By Synthesis Type
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2023
16.10.2.1. By Indication
16.10.2.2. By Manufacturing Mode
16.10.2.3. By Synthesis Type
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2023
16.11.2.1. By Indication
16.11.2.2. By Manufacturing Mode
16.11.2.3. By Synthesis Type
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2023
16.12.2.1. By Indication
16.12.2.2. By Manufacturing Mode
16.12.2.3. By Synthesis Type
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2023
16.13.2.1. By Indication
16.13.2.2. By Manufacturing Mode
16.13.2.3. By Synthesis Type
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2023
16.14.2.1. By Indication
16.14.2.2. By Manufacturing Mode
16.14.2.3. By Synthesis Type
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2023
16.15.2.1. By Indication
16.15.2.2. By Manufacturing Mode
16.15.2.3. By Synthesis Type
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2023
16.16.2.1. By Indication
16.16.2.2. By Manufacturing Mode
16.16.2.3. By Synthesis Type
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2023
16.17.2.1. By Indication
16.17.2.2. By Manufacturing Mode
16.17.2.3. By Synthesis Type
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2023
16.18.2.1. By Indication
16.18.2.2. By Manufacturing Mode
16.18.2.3. By Synthesis Type
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2023
16.19.2.1. By Indication
16.19.2.2. By Manufacturing Mode
16.19.2.3. By Synthesis Type
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2023
16.20.2.1. By Indication
16.20.2.2. By Manufacturing Mode
16.20.2.3. By Synthesis Type
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2023
16.21.2.1. By Indication
16.21.2.2. By Manufacturing Mode
16.21.2.3. By Synthesis Type
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2023
16.22.2.1. By Indication
16.22.2.2. By Manufacturing Mode
16.22.2.3. By Synthesis Type
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2023
16.23.2.1. By Indication
16.23.2.2. By Manufacturing Mode
16.23.2.3. By Synthesis Type
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Indication
17.3.3. By Manufacturing Mode
17.3.4. By Synthesis Type
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Novartis AG (Sandoz)
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. Merck & Co., Inc
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Lonza
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Sun Pharmaceutical Industries Ltd.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. Teva Pharmaceutical Industries Ltd.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Aurobindo Pharma Ltd
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Fermion (Orion Corporation)
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Avra Laboratories Pvt Ltd
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. LGM Pharma
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. Rochem International Inc
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology

Methotrexate Drug Market

Methotrexate Drug Market Forecast by Psoriasis and Rheumatoid Arthritis Indication for 2024 to 2034